Catalyst

Slingshot members are tracking this event:

Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
NBIX Community voting in process

Additional Information

Additional Relevant Details The T-Force GREEN study is a randomized, double-blind, placebo-controlled, multi-dose, parallel group, study of up to 90 children and adolescents. Subjects will receive once-daily dosing of valbenazine during a six-week treatment period to assess the safety, tolerability and efficacy of valbenazine in pediatric Tourette patients. The primary endpoint of this study is the change from baseline of the Yale Global Tic Severity Scale between placebo and active treatment groups at the end of week six.

http://phoenix.corpo...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 02, 2016
Related Keywords Phase Ii Clinical Study, Vmat2 Inhibitor, Valbenazine, Tourette Syndrome